Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 24, 2017

DrugPatentWatch Database Preview

MEGACE Drug Profile

« Back to Dashboard

What is the patent landscape for Megace, and when can generics launch?

Megace is a drug marketed by Bristol Myers Squibb and Endo Pharms Inc and is included in three NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MEGACE is megestrol acetate. There are eighteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.

Summary for Tradename: MEGACE

Suppliers / Packagers: see list1
Bulk Api Vendors: see list71
Clinical Trials: see list6
Patent Applications: see list6,732
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MEGACE at DailyMed

Pharmacology for Tradename: MEGACE

Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
megestrol acetate
SUSPENSION;ORAL020264-001Sep 10, 1993DISCNYesNo► Subscribe► Subscribe
Endo Pharms Inc
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes9,107,827► Subscribe ► Subscribe
Endo Pharms Inc
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes7,101,576► Subscribe ► Subscribe
Endo Pharms Inc
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes9,040,088► Subscribe ► Subscribe
Bristol Myers Squibb
megestrol acetate
TABLET;ORAL016979-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents
  • Obtain formulation and manufacturing information

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus